Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Ovarian cancer stem cells: elusive targets for chemotherapy.

Guddati AK.

Med Oncol. 2012 Dec;29(5):3400-8. doi: 10.1007/s12032-012-0252-6. Epub 2012 May 26. Review.

PMID:
22638913
2.

Characterization of disease progression in ovarian cancer by utilizing 'chemograms' of ovarian cancer stem cells.

Guddati AK, Shaheen S.

J Chemother. 2013 Jun;25(3):184-91. doi: 10.1179/1973947812Y.0000000058.

PMID:
23783145
3.

Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets.

Ahmed N, Abubaker K, Findlay JK.

Mol Aspects Med. 2014 Oct;39:110-25. doi: 10.1016/j.mam.2013.06.002. Epub 2013 Jun 25. Review.

PMID:
23811037
4.

Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.

Ahmed N, Abubaker K, Findlay J, Quinn M.

J Cell Biochem. 2013 Jan;114(1):21-34. doi: 10.1002/jcb.24317. Review.

PMID:
22887554
5.

Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance.

Wang X, Li X, Fu X, Bai M, Li X, Mei Q, Nie J, Wu Z, Han W.

Curr Protein Pept Sci. 2015;16(4):270-8. Review.

PMID:
25929861
6.

Targeting ovarian cancer-initiating cells.

Murphy SK.

Anticancer Agents Med Chem. 2010 Feb;10(2):157-63. Review.

PMID:
20184540
7.

Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome.

Luo L, Zeng J, Liang B, Zhao Z, Sun L, Cao D, Yang J, Shen K.

Exp Mol Pathol. 2011 Oct;91(2):596-602. doi: 10.1016/j.yexmp.2011.06.005. Epub 2011 Jul 20.

PMID:
21787767
8.

Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.

Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin-Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD.

Cancer. 2011 Dec 15;117(24):5519-28. doi: 10.1002/cncr.26215. Epub 2011 Jun 20.

9.
10.

Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.

Ma L, Lai D, Liu T, Cheng W, Guo L.

Acta Biochim Biophys Sin (Shanghai). 2010 Sep;42(9):593-602. doi: 10.1093/abbs/gmq067. Epub 2010 Aug 12.

PMID:
20705681
11.

Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.

Lim MC, Song YJ, Seo SS, Yoo CW, Kang S, Park SY.

Onkologie. 2010;33(6):324-30. doi: 10.1159/000313823. Epub 2010 May 14. Review.

PMID:
20523098
12.

[Importance of the tumor stem cell hypothesis for understanding ovarian cancer].

Vochem R, Einenkel J, Horn LC, Ruschpler P.

Pathologe. 2014 Jul;35(4):361-70. doi: 10.1007/s00292-014-1910-6. Review. German.

PMID:
24992976
13.

Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

Aguilar-Gallardo C, Rutledge EC, Martínez-Arroyo AM, Hidalgo JJ, Domingo S, Simón C.

Stem Cell Rev. 2012 Sep;8(3):994-1010. doi: 10.1007/s12015-011-9344-5. Review.

PMID:
22278130
14.

Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.

Meirelles K, Benedict LA, Dombkowski D, Pepin D, Preffer FI, Teixeira J, Tanwar PS, Young RH, MacLaughlin DT, Donahoe PK, Wei X.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2358-63. doi: 10.1073/pnas.1120733109. Epub 2012 Jan 27.

15.

Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.

Ahmed N, Abubaker K, Findlay J, Quinn M.

Curr Cancer Drug Targets. 2010 May;10(3):268-78. Review.

PMID:
20370691
16.

Surgical cytoreduction for recurrent epithelial ovarian cancer.

Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K.

Cochrane Database Syst Rev. 2013 Feb 28;2:CD008765. doi: 10.1002/14651858.CD008765.pub3. Review.

PMID:
23450588
17.

Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.

Kim TH, Suh DH, Kim MK, Song YS.

Biomed Res Int. 2014;2014:132702. doi: 10.1155/2014/132702. Epub 2014 Jun 24. Review.

18.

Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant.

Hu L, McArthur C, Jaffe RB.

Br J Cancer. 2010 Apr 13;102(8):1276-83. doi: 10.1038/sj.bjc.6605626. Epub 2010 Mar 30.

19.

Ovarian cancer stem cells: a new target for cancer therapy.

Zhan Q, Wang C, Ngai S.

Biomed Res Int. 2013;2013:916819. doi: 10.1155/2013/916819. Epub 2013 Jan 30. Review.

20.

Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells: sensitivity of ovarian cancer cells to phyto-active chemicals.

Chen S, Cooper M, Jones M, Madhuri TK, Wade J, Bachelor A, Butler-Manuel S.

Cell Biol Toxicol. 2011 Apr;27(2):133-47. doi: 10.1007/s10565-010-9176-0. Epub 2010 Sep 26.

PMID:
20872277
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk